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ABSTRACT 
Objective: The objective of the study is to determine the occurrence, frequency, and severity of significant drug-drug interactions in stroke patients, 
with an emphasis on post complications and their symptomatic management. 
Methods: A prospective observational study was carried out for 6 mo at Osmania General Hospital, a Tertiary Care Teaching Hospital. The prescriptions 
taken by stroke patients throughout their hospital stay were analyzed for possible interactions using-Micromedex-2 (Thomson Reuters) × 2.0. 
Results: A total of 130 prescriptions was analyzed in the study in which 141 drug-drug interactions were found with a male predominance of 
85.4%. The majority of interactions were of moderate severity (74.46%) and pharmacokinetics (67.37%) in nature. Among the clinical 
consequences, decreased atorvastatin efficacy (49.10%) was found to be the highest. The class of drugs most commonly involved in drug-drug 
interactions was found to be anti-epileptics and statins. 60.15% of the study population were identified with one complication, among which 
seizures account for 15% of patients. All the complications allied with the condition were treated with drug classes in the study population. 
Conclusion: This study highlighted the exigency for screening prescriptions of cerebrovascular accident patients for potential drug-drug 
interactions (pDDIs). Brain edema and seizure were the most accountable complications identified in the study population. The early detection of 
these problems can improve stroke outcomes and can reduce the mortality or disability rate. 
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INTRODUCTION 
Innocuous use of modern and conventional medicines is a striving 
objective for all of us. Medicines have brought massive benefits, but 
no medicine is 100% safe and sound for all people. While some 
medicines can gravely injure or even kill, chiefly most of them have 
beneficial effects for the people even while they may cause 
intermittent minor harm such as headache, rash, or tiredness [1].  
Drug therapy is an essential part of disease management. The use of 
multiple drugs which are required either to manage a single disease 
or co-morbidities can cause harmful interactions between them [2]. 
Drug-related problems such as adverse drug reactions, drug-drug 
interactions, idiosyncratic reactions, and hypersensitivity were 
major challenges in clinical practice [3]. Potential DDIs are observed 
to be one of the most frequently appearing challenges that may 
amend the drug pharmacokinetics and pharmacodynamics, thus 
altering the overall therapeutic response [4]. 
An interaction is said to occur when the effects of one drug are 
altered by the co-administration of another drug, herbal medicine, 
food, drink, or other environmental chemical agents. The net effect 
of the combination may manifest as an additive or enhanced effect of 
one or more drugs, antagonism of the effect of one or more drugs, or 
any other alteration in the effect of one or more drugs [5]. 
Certain conditions such as multiple disorders, chronic diseases, and 
polypharmacy may enhance the risk of potential DDIs. Drug 
therapies in critically ill patients are often complicated by the 
altered physiology and co-existence of multiple co-morbidities that 
warrant poly-pharmacy. The management of the disease typically 
requires the use of more than one drug. When patients have multiple 
symptoms, it becomes decisive to prescribe copious drugs. Drug-
drug interactions usually occur amidst drugs with a low therapeutic 
index, with a small difference between their therapeutic and toxic or 
lethal doses [6]. This means the slightest change in the dosage of a 
drug can produce dangerous and harmful events. 
According to the World Health Organization (WHO), stroke 
(Apoplexy, the word used by Hippocrates) is a condition 
“characterized by rapidly developing clinical symptoms and/or signs 
of focal, and at times global, loss of cerebral function, with symptoms 
lasting more than 24 h leading to death with no apparent cause 
other than that of vascular origin” [7]. There are two main types of 
cerebrovascular accidents or stroke: Ischemic stroke and 
hemorrhagic stroke. In both cases, part of the brain is deprived of 
blood and oxygen, causing the brain cells to die [8]. 
Worldwide, cerebrovascular diseases are accountable for 6.15 
million deaths [9]. Stroke is the second leading cause of death 
worldwide and can lead to stern, long-term disability. In addition to 
neurological deficits, diverse medical complications can arise 
following a stroke [10]. Furthermore, complications from stroke 
meddle with early rehabilitation, therapy and prevent recovery [11]. 
Thus, the study aims to determine the occurrence, frequency, and 
severity of significant drug-drug interactions in stroke patients, with an 
emphasis on post complications and their symptomatic management. 
MATERIALS AND METHODS 
Study design and population 
A prospective observational study was carried out for a period of 6 
mo (November 2019-April 2020) in the General medicine 
department and Neurology IPD of Osmania General Hospital in 
Hyderabad (Telangana), which is an 1100 bedded tertiary care 
hospital with male and female departments, the largest government 
clinical setting in southern India. Ethical approval was obtained 
from the institutional ethics committee (MCP/IEC/PD/PR/45) 
before the initiation of the study according to the institution's 
regulations. Prescriptions of 130 stroke patients admitted 
consecutively to inpatient wards of a tertiary care hospital were 
analyzed during this study. Prescriptions with two or more drugs 
prescribed throughout the hospitalization were only preferred for 
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the study. The study population comprised of patients above18 y 
and who had a length of stay>24 h. Stroke patients with other co-
morbidities were included and patients unwilling to participate, visit 
the outpatient department, pregnant and lactating women were 
excluded from the study. 
Data collection 
Demographic information (age and gender), number of drugs 
prescribed, habit history (alcohol and tobacco), length of hospital 
stays, general examination with lab parameters, main diagnosis, 
medication chart, and follow-up details were obtained from the 
patient's case record form. Laboratory data reports and clinical 
records of the patient's previous medical history were collected from 
the patient/caretaker through an interview. Certain demographic 
characteristics were considered to identify the prognosticators of 
DDIs, such as patient characteristics [length of hospital stay], and the 
number of drugs per prescription. The medications taken by the 
stroke patients during their hospital stay were analyzed for possible 
DDIs via an electronic database-Micromedex x 2.0. Available data on 
prescriptions included are Name, strength, frequency, and quantity of 
medications dispensed. The data obtained was used to categorize 
interactions based on the mechanism as pharmacokinetic or 
pharmacodynamics. The interactions were classified into mild, 
moderate, and severe according to the severity scale.  
Drug-drug interaction checker 
Micromedex electronic database tool was used to identify and 
analyze the pattern of DDIs [12]. Micromedex contains a separate 
section on DDIs known as the Drug-REAX System. On entering the 
drugs one by one, the program lists the possible DDIs and 
categorizes DDIs according to their interaction effect, severity 
(contraindicated, serious, moderate, mild, and unknown), onset 
(rapid, delayed, and unspecified), management, documentation 
status (excellent, good, fair, poor, unlikely, and unknown), and 
literature reports. 
Statistical analysis 
The data subjected to statistical analysis in the present study 
included the number of drugs prescribed, length of hospital stay, and 
number of DDIs. The data were analyzed for descriptive statistics 
and further with an independent t-test for the test of significance at 
the 5 % level using Microsoft Excel 2010.  
RESULTS 
A total of 130 stroke prescriptions was included in the study, and 
among them, hemorrhagic stroke was 71 (54.61%), followed by 
ischemic stroke 59 (45.38%). The average stay in the hospital was 
13 d. The analysis of stroke prescriptions allowed us to identify 141 
interactions among 86 patients, with an average number of drugs 
taken of 7.15. All the patient prescriptions were analyzed during the 
study period and it was found that 53 (37.6%) patients were 
confirmed with a minimum of one DDI. A substantial proportion of 
patients with drug-drug interactions are occupied by males 111 
(85.4%). Patients with an age group of 41-60 y had 82 (58.15%) 
DDIs and were followed by other age groups. The patient 
characteristics are summarized in (table 1). 
  
Table 1: Demographic profile of stroke patients 
Parameter Total no. of patients Percentage 
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Fig. 1: Drug utilization pattern 
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The most common drug classes (fig. 1) prescribed to the stroke 
patients were supplemented, anti-hypertensives, and lipid-lowering 
agents followed by diuretic and PPIs. The incidence rate of DDIs in 
the present study was anticipated to be 86%. 
 
 
Fig. 2: Type of interactions found from database 
 
 
Fig. 3: Type of pDDIs based on the severity scale 
 
This study revealed there were 105 moderate, 25 major, and 11 
minor interactions (fig. 3). Among these, pharmacokinetic 
interactions were 95 and the pharmacodynamics interactions were 
40 followed by unknown 6 in (fig. 2). 
 
Table 2: List of commonly occurring drug-drug interactions 
Interacting pair  Clinical consequences 
Aspirin/Clopidogrel Increased Risk of Bleeding 
Amlodipine/Clopidogrel Increased Risk of Thrombotic Events 
Phenytoin/Calcium Carbonate Decreased Exposure of Phenytoin 
Aspirin/Metformin Increased Risk of Hypoglycemia 
Phenytoin/Atorvastatin Decreased Atorvastatin Plasma Concentration and Efficacy 
Aspirin/Calcium Carbonate Decreased Salicylates Effectiveness 
Enalapril/Aspirin Decreased Effectiveness of Enalapril 
Phenytoin/Acetaminophen Increased Risk of Hepatotoxicity 
In our study, the above-mentioned list of drug-drug interactions-aspirin/clopidogrel, amlodipine/clopidogrel, aspirin/metformin, and 
phenytoin/calcium carbonate were of major severity; whereas the interacting rest pairs were of moderate severity 
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Fig. 4: Bar graph showing various clinical consequences occurring due to DDI’s, Among the various clinical consequences, decreased 
atorvastatin efficacy (49.10%) was found to be the highest 
 
Table 3: Management options required for DDI’s 
 Management   Number of DDIs   Percentage  
Dose Adjustment  69  44.23%  
Monitor for Biochemical Parameters  23  14.74%  
Dose-Titration  22  14.10%  
Monitor for Drug Levels  09  5.76%  
Avoid Combination  07  4.48%  
Monitor for Sign and Symptoms  07  4.48%  
No Management Required  06  3.84%  
Risk–Benefit Analysis  06  3.84%  
Alternative Medication  05  3.20%  
Monitor for Electrolyte Levels  02  1.28%  
 It was noted that the most common management plan found for most of the DDIs was dose adjustment accounted for the highest percentage 
(44.23%). 
 
Table 4: Type of complication and their percentage 
Complications  No. of patients Percentage 
Edema 105 65.62% 
Seizures 26 16.25% 
Aspiration Pneumonitis 18 11.25% 
Urinary Tract Infection 11 6.87% 
It was noted that 60.15% of the study population were identified with one complication, among which seizures account for 15% of patients. 68% of 
patients developed brain edema, incorrigible by CT scans in 2-5 d of their disease onset. The individual percentages of patients with complications 
are summarized in (table 4). 
 
Table 5: Drug utilization in the therapy of post-stroke complications 
Complications A drug used No. of patients 
Edema Mannitol 105 
Seizures Phenytoin 26 
 Aspiration Pneumonitis Amoxicillin 18 
 Urinary–Tract Infection Levofloxacin 11 
 
All the complications allied with the condition were treated with 
drug classes in the study population. 
Edema, due to the pathophysiological changes of ischemia, was 
controlled by using an osmotic diuretic (mannitol) in 105 patients 
(65.62%). The different complications and their respective 
management options are listed in (table 5).  
Association between the risk factors and incidence of DDI’s in 
stroke patients 
Length of hospital stay and number of medicines prescribed were 
assessed to determine their connection with the likelihood of 
incidence of DDIs. The data analysis revealed a negative correlation 
between these factors and the incidence of DDI’s. 
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Table 6: Descriptive statistics and correlation between length of hospital stay and number of DDI’s 
Parameters (N) Mean Median SD Standard error Sample variance Confidence level (95%) 
Length of hospital stay 130 13.5 13.5 3.605 1.040 13 2.290 
No. of DDI’s 130 11.75 9 10.549 3.045 111.2 6.702 
Parameters P-value (one tail) P-value (two tail) R-value Linear regression equation 
Length of hospital stay 
No. of DDI’s 
0.29604 0.59208  -0.237 y =-0.4273x+18.1 
R² = 0.0176 
 
 
Fig. 5: Linear regression between the length of hospital stay and number of DDI, Therefore, there is a negative correlation between the 
length of hospital stay and the number of drug interactions 
 
Table 7: Descriptive statistics and correlation between no. of medicines prescribed and number of DDI’s 
Parameters N Mean Median SD Standard error Sample variance Confidence level (95%) 
No. of drugs prescribed 130 8 8 2.738 0.912  7.5  2.105  
No. of DDI’s 130 15.66 18 11.045 3.681  122  8.490  
Parameters P-value  (one tail)  P-value  (two tail) R-value  Linear regression equation  
No. of drugs prescribed  
No. of DDI’s 
0.0301  0.0603  -0.264  y =-1.0667x+24.2 
R² = 0.0699 
 
 
Fig. 8: Linear regression between the number of medicines and number of DDI's, Therefore, there is a negative correlation between the 
number of medicines and the number of drug interactions 
 
DISCUSSION 
The present study revealed the overall incidence of pDDIs among 
130 stroke patients at Osmania General Hospital. Out of 130 stroke 
patients, 111 (85.38%) were males and 19 (14.61%) were females. 
The occurrence of stroke was more in men than women. This was 
similar to the study conducted by N. Anitha et al. (63.8% were male 
and 36.2% were female) (2020) [18]. 
Drug-drug interactions (DDI's) are the major concern for patients, 
and this risk increases as larger numbers of medications are 
frequently used to handle intricate conditions. DDI has always been 
a subject of concern in the effective management of a patient's ill 
health.  
The average number of drugs per prescription was 7.15. The finding 
was found to be similar to the study findings conducted by 
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Thammisetty D. P et al., (7.2) (2021) [19]. The overall incidence rate of 
pDDIs in the present study was found to be 86% which is more than 
the study conducted by Virendra KP et al., (30.67%) (2011) [20]. 
A sum of 141 drug-drug interactions was found in 130 patients with a 
male predominance of 85.38%. The predominance was similar to the 
studies conducted by Virendra KP et al. (males 66%) and Sushmita et 
al., (males-61%) [20]. The most common drug classes involved in DDIs 
were the anti-epileptics, stations, antiplatelets, and antihypertensives 
as shown in fig. 1. Among this phenytoin, atorvastatin, aspirin, 
clopidogrel, amlodipine, furosemide, and enalapril were the drugs that 
caused common clinically significant drug interactions. 
On analyzing the mechanism of drug interaction, pharmacokinetics 
type of interactions (67.37%) was found to be in greater number 
compared to pharmacodynamic drug interactions (28.36%) followed 
by the interactions of unknown mechanism (4.25%). This finding was 
found to be similar to the study findings conducted. On account of 
severity assessment of the reactions, the majority of the reactions 
were categorized as moderate (74.46%), followed by major severity 
(17.73%). The finding was similar to a study conducted. 
A strong inverse correlation was found between the length of 
hospital stay and DDIs (r =-0.237, p-value is = 0.29604). The similar 
significant negative correlation was also found between the number 
of medicines prescribed and DDI’s (r =-0.264, p-value = 0.0301). 
The most common management plan found for most of the DDIs was 
Dose Adjustment (44.23%). These results were following the 
observation of studies conducted. The suggested action to be taken 
in most cases was monitoring biochemical parameters, signs and 
symptoms,+-electrolyte levels.  
Our study revealed the various medical and neurological 
complications which are allied to stroke following the acute attack. 
The identification of such complications in the initial days of effect 
helps to perceive the early preventability. In our study, a high 
incidence of patients was with one complication i.e., edema (67%). 
The result was in congruence with the observation of earlier 
reported studies. In the current study, all the identified 
complications were managed as per their standard guidelines for 
symptomatic relief.  
CONCLUSION 
From a pharmacological perspective, drug-drug interactions are real 
with indecisive clinical implications. Our study highlighted the 
bodice, which was high in stroke patients above 40 y. The majority 
of interactions were pharmacokinetic, having moderate severity. 
The significant proportions of patients with DDIs were occupied by 
males followed by the females.  
In this study, pDDIs mainly occurred between anti-epileptics, stations 
antiplatelet, and antihypertensives. A clinical pharmacist plays a vital 
role in identifying the timely drug interactions and reporting them to 
the physician which may be helpful to prevent potentially detrimental 
drug interactions. Long-term complications are frequent in stroke 
survivors. Special care should be provided to patients with risk factors 
for post-stroke medical complications, including old age, poor initial 
motor function, poor swallowing function, and pre-existing 
morbidities. The accurate identification of the risk factors allied with 
the stroke patients prior; help us to bring down the cost burden along 
with improvement in the quality of life effectively.  
LIMITATION OF STUDY 
The sample size of the study was relatively small due to the short 
duration of the study. The current study was attributable only to a 
single hospital. The study was conducted without any intervention 
component. Further prospective studies are needed for the 
observation, identification, and management of DDIs among stroke 
patients. 
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